Thomas Tarita O, Small William, Fleming Mark, Kang Song, Hoefer Richard A
Department of Radiation Oncology, Stritch School of Medicine, Loyola University, Chicago, IL, United States.
Cardinal Bernardin Cancer Center, Maguire Center, Loyola University Medical Center, Maywood, IL, United States.
Front Oncol. 2018 Mar 23;8:12. doi: 10.3389/fonc.2018.00012. eCollection 2018.
Neoadjuvant therapy including chemotherapy alone or concurrent chemotherapy with external bream radiation is a standard treatment strategy for borderline resectable pancreatic adenocarcinoma and is also used routinely for primary operable cancers at some institutions (1). The use of intraoperative radiation therapy (IORT) has been limited largely because of the logistical issues in delivery of radiation during surgery (2). This is the first reported case of a borderline resectable pancreas cancer patient who underwent neoadjuvant chemo-radiation therapy followed by resection with the use of IORT using the mobile IntraBeam device to boost the resection bed and improve local control by dose escalation.
新辅助治疗,包括单纯化疗或与体外束放射同步化疗,是可切除边缘的胰腺腺癌的标准治疗策略,在一些机构也常规用于原发性可手术癌症(1)。术中放射治疗(IORT)的应用在很大程度上受到限制,原因是手术期间放射治疗的实施存在后勤问题(2)。这是首例报道的可切除边缘的胰腺癌患者,该患者接受了新辅助放化疗,随后使用移动体内照射装置进行IORT切除,以增加切除床的剂量并通过剂量递增改善局部控制。